Search Medical Condition
Please enter condition
Please choose location from dropdown

Burton-upon-Trent, United Kingdom Clinical Trials

A listing of Burton-upon-Trent, United Kingdom clinical trials actively recruiting patients volunteers.

RESULTS

Found (47) clinical trials

Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS

This is an event driven study to reach statistical power given all other assumptions. Subjects will visit the clinic 1 month after randomization and at regular intervals thereafter. Additionally, for any subject prematurely discontinuing study medication, assessments will be conducted every 6 months for the collection of study endpoints. Those ...

Phase

0.0 miles

Learn More »

Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy

STAMPEDE (also known as MRC PR08) is a multi-arm multi-stage (MAMS) randomised controlled trial recruiting in the UK and Switzerland. It aims to evaluate multiple therapeutic strategies in the management of high-risk locally advanced and metastatic hormone-nave prostate cancer. Each novel treatment strategy is compared against a single, contemporaneous control ...

Phase

0.0 miles

Learn More »

Prostate Adenocarcinoma TransCutaneous Hormones

OBJECTIVES Primary Compare the progression-free survival and overall survival of patients with locally advanced or metastatic prostate cancer treated with transcutaneous estrogen patches vs luteinizing hormone-releasing hormone analogues. Secondary Compare the cardiovascular system-related morbidity and mortality in patients treated with these regimens Compare the activity of these treatments, in terms ...

Phase

0.0 miles

Learn More »

A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment

Chlorambucil (Chl) has been the mainstay of CLL treatment for half a century. However, frontline treatment has improved considerably over the last decade, first by the advent of fludarabine plus cyclophosphamide (FC), and more recently by the addition of the anti-CD20 antibody, rituximab, to FC. Although FC-based regimens are considerably ...

Phase

0.0 miles

Learn More »

The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd)

Study design: Randomised, controlled, multi-centre, open-label, phase III trial (with a single intervention registration phase). Primary Objectives The primary objectives of this study are to determine: The impact on Depth of Response (DoR: less than VGPR versus VGPR or better) when salvage ASCT conditioning is augmented by the addition of ...

Phase

0.0 miles

Learn More »

Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)

Multiple myeloma is the second most common hematologic malignancy in the European Union (EU), responsible for an estimated 21,000 deaths in the EU in 2008. For patients that relapse or are refractory to current standard treatment (combination of bortezomib/lenalidomide, dexamethasone and an alkylating agent) there are few options available and ...

Phase

0.8 miles

Learn More »

Follow-Up Study of Patients Who Have Undergone Surgery for Stage I Stage II or Stage III Colorectal Cancer

OBJECTIVES: Primary - To assess the effect of augmenting symptomatic follow-up in primary care with two intensive methods of follow-up (monitoring tumor marker in primary care and intensive imaging in hospital) on survival of patients with stage I, II, or III colorectal cancer who have undergone curative resection. Secondary - ...

Phase N/A

0.8 miles

Learn More »

Dalteparin in Preventing Blood Clots in Patients With Lung Cancer

OBJECTIVES: Primary - Determine whether the addition of dalteparin results in improved survival. Secondary - Determine venous thrombotic event-free survival and metastasis-free survival. - Determine serious adverse events in patients treated with this drug. - Determine the toxicity of this drug in these patients. - Determine the quality of life, ...

Phase

0.8 miles

Learn More »

Studying DNA in Patients With Stage I Stage II Stage III or Stage IV Ovarian Epithelial Cancer

OBJECTIVES: - To determine if DNA methylation patterns and expression of differentially methylated genes taken before chemotherapy can predict patient outcome with regard to progression-free survival. - To evaluate whether DNA methylation can predict response assessed by RECIST criteria and CA 125 response. - To evaluate the specificity and sensitivity ...

Phase N/A

0.8 miles

Learn More »

CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer Fallopian Tube Cancer or Primary Peritoneal Cancer Who Are Receiving Tamoxifen

OBJECTIVES: - Determine the percentage of patients with relapsed advanced ovarian carcinoma, fallopian tube carcinoma, or primary peritoneal carcinoma who have a log linear rise in CA 125 levels. - Determine whether the log linear part of the curve is consistent enough to allow comparison of the slope before and ...

Phase

0.8 miles

Learn More »